ZIVO Bioscience, Inc. Annual Shareholder Meeting and Conference Call Slated for November 7, 2018 in Detroit, Michigan

ZIVO Bioscience, Inc. Annual Shareholder Meeting and Conference Call Slated for November 7, 2018 in Detroit, Michigan

KEEGO HARBOR, MI - ZIVO Bioscience, Inc., (OTCQB: ZIVO) a Michigan-based biotech firm, invites shareholders, analysts and partners to its annual shareholder meeting on Wednesday, November 7, 2018, beginning at 10:00AM EDT. The event will be held at the Westin Hotel located within the Detroit Metropolitan Airport (DTW) Midfield Terminal building, in the meeting room levels below the main atrium. The Company's management will share its progress on various research and product development efforts over the past year.

The shareholder meeting will begin promptly at 10:00AM EDT on Wednesday, November 7, 2018. Those who cannot attend in person are invited to call in to the conference line provided for this event.

ZIVO Bioscience, Inc. Annual Shareholder Meeting and Conference Call

Conference Date: November 7, 2018
Conference Start Time: 10:00 AM Eastern Daylight Time
Participants are encouraged to call in 5-10 minutes prior to start
Participant Dial-In Numbers:
TOLL-FREE 1-800-458-4148

A replay of the Meeting and Conference Call will be available as follows:

Replay Dial-In Numbers:
TOLL-FREE 1-844-512-2921
From: November 7, 2018 @ 1:00 PM Eastern Daylight Time
To: November 21, 2018 @ 11:59 PM Eastern Daylight Time
Replay PIN Number: 2518576

About ZIVO Bioscience, Inc.

ZIVO Bioscience, Inc. (OTCQB: ZIVO) is a Michigan-based biotech company engaged in the investigation of the health benefits of bioactive compounds derived from its proprietary algal cultures, and the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologics and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically focused on autoimmune modulation.

Safe Harbor Statement

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise